Transaction · 0001969082-26-000011

Cislini Jeff

Cislini Jeff, SVP, GC, reported an open-market or private sale at Revolution Medicines, Inc. involving 765.000000 shares for an estimated $158599.88. Reported holdings after the transaction were 51776.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SSVP, GC
RVMDRevolution Medicines, Inc.
Filing timeSep 29
Trade dateSep 25, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position traded1.46%Shares sold ÷ (holdings after + shares sold). Estimated position before: 52,541 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$204.48
Pre-filing
1mo ago +4.3%1w ago -6.6%1d ago -2.3%
Returns since
7d30d90d180d1y

RVMD price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
RVMD since 2026-09-29Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001969082-26-000011
Common Stock
Transaction date
Sep 25, 2026
Filed Sep 29, 2026, 10:00 PM · 4d delay
Shares
765 sh
$207.32 per share
Estimated value
-$158k
Computed from shares × price
Holdings after
51.7k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Repeat Seller 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

SVP & General Counsel

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.

  2. F2

    Includes 37,088 restricted stock units.

Original filing · 0001969082-26-000011
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

RVMD